School of Medical Laboratory Sciences, Institute of Health, Jimma University, Jimma, Ethiopia.
College of Veterinary Medicine, Samara University, Samara, Ethiopia.
PLoS One. 2022 Feb 10;17(2):e0263625. doi: 10.1371/journal.pone.0263625. eCollection 2022.
Community-directed treatment with ivermectin (CDTi) is the primary strategy employed to control and eliminate human onchocerciasis in Ethiopia. After long-term mass distribution for onchocerciasis, ivermectin is expected to have additional benefits beyond the envisioned targets by reducing the burden of other co-endemic parasitic infections as to STHs. To date, studies focused on the collateral impact of CDTi on STH in Ethiopia are scanty. Two community-based cross-sectional surveys (baseline in 1997 and post-CDTi in 2017) were conducted to evaluate the impact of long-term CDTi employed to control and eliminate onchocerciasis on the burden of STH infections in Yeki district of southwest Ethiopia. Stool samples were collected and examined using Ritchie`s concentration and Kato-Katz techniques in the baseline and current study, respectively. Overall, 188(38.3%, 95% Confidence interval (CI) 34.1-42.7%) individuals were positive at least for any of the STH species from 491 study participants in the post-CDTi. The prevalence of A. lumbricoides, hookworms, and T. trichiura was 11.2% (95% CI 8.7-14.3%), 16.3% (95% CI 13.3-19.8%), and 29.9% (95% CI 26.1-34.1%), respectively. Individuals aged 5-9 years had a significantly higher prevalence of A. lumbricoides (Adjusted odds ratio (AOR) 6.5, 95% CI 1.7-25.4), T. trichuria (AOR 8, 95% CI 2.6-25.1), and any STH infection (AOR 5, 95% CI 1.7-14.7) than those of ≥ 51 years. Also, significantly higher prevalences of T. trichuria infection were observed in individuals aged 10-14 years (AOR 4.1, 95% CI 1.7-9.9), 15-20 years (AOR 3.1, 95% CI 1.2-8.1), 21-30 years (AOR 2.4, 95% CI 1.1-5.5), and 31-40 years (AOR 3.2, 95% CI 1.3-7.5) compared with those of ≥ 51 years. The prevalence of A. lumbricoides was significantly higher in males (AOR 0.5, 95% CI 0.3-0.9). Of the 491 study participants, only data from 400 individuals who had not been involved in a mass drug administration (MDA) with other STH anthelmintics were considered in the comparative analysis. Before CDTi, the prevalence of A. lumbricoides, T. trichiura, hookworm, and any STH infection was 47.1% (95% CI 41.6-52.7%), 3.3% (95% CI 1.8-5.9%), 37.9% (95% CI 32.7-43.5%), and 58.8% (95% CI 53.2-64.1%), respectively. Long-term CDTi considerably reduced the prevalences of A. lumbricoides and hookworm by 76.2% and 56.9%, respectively (p < 0.001). Nonetheless, CDTi did not affect the prevalence of T. trichiura infection and, in contrast, it was significantly higher in the current study (P < 0.001). Overall post-CDTi prevalence of any STH infection was considerably lower than reported in the baseline (p < 0.001). It is evidenced that long-term CDTi for onchocerciasis control and elimination had additional benefits by reducing the prevalence of STH infections specifically of A. lumbricoides and hookworm, but had no impact on infections with T. trichuria. Our finding of additional health benefits of large-scale ivermectin administration taking it will aid to increase positive engagement and sustain participation of communities during MDA campaigns, and strengthen governmental and non-governmental organizations (NGOs) support for the undergoing national onchocerciasis elimination program.
社区导向伊维菌素治疗(CDTi)是控制和消除埃塞俄比亚人类盘尾丝虫病的主要策略。在长期大规模分发伊维菌素治疗盘尾丝虫病之后,预计伊维菌素除了预期的目标之外,还将通过减轻其他共流行寄生虫感染(如肠道寄生虫感染)的负担,从而带来额外的益处。迄今为止,关于 CDTi 对埃塞俄比亚肠道寄生虫感染的间接影响的研究很少。在埃塞俄比亚西南部耶基区进行了两项基于社区的横断面调查(基线在 1997 年,CDTi 后在 2017 年),以评估长期用于控制和消除盘尾丝虫病的 CDTi 对肠道寄生虫感染负担的影响。基线和当前研究中分别使用 Ritchie 的浓缩和加藤氏技术收集和检查粪便样本。在 CDTi 后,491 名研究参与者中至少有 188 人(95%置信区间(CI)为 34.1-42.7%)对任何肠道寄生虫物种呈阳性。鞭虫、钩虫和蛔虫的患病率分别为 11.2%(95%CI 8.7-14.3%)、16.3%(95%CI 13.3-19.8%)和 29.9%(95%CI 26.1-34.1%)。5-9 岁的个体感染鞭虫(调整后的优势比(AOR)6.5,95%CI 1.7-25.4)、蛔虫(AOR 8,95%CI 2.6-25.1)和任何肠道寄生虫感染(AOR 5,95%CI 1.7-14.7)的风险显著高于≥51 岁的个体。此外,10-14 岁(AOR 4.1,95%CI 1.7-9.9)、15-20 岁(AOR 3.1,95%CI 1.2-8.1)、21-30 岁(AOR 2.4,95%CI 1.1-5.5)和 31-40 岁(AOR 3.2,95%CI 1.3-7.5)的个体感染蛔虫的风险显著高于≥51 岁的个体。男性感染鞭虫的风险显著更高(AOR 0.5,95%CI 0.3-0.9)。在 491 名研究参与者中,只有未参与其他肠道寄生虫驱虫药物大规模药物治疗(MDA)的 400 名个体的数据才被纳入比较分析。在 CDTi 之前,鞭虫、蛔虫、钩虫和任何肠道寄生虫感染的患病率分别为 47.1%(95%CI 41.6-52.7%)、3.3%(95%CI 1.8-5.9%)、37.9%(95%CI 32.7-43.5%)和 58.8%(95%CI 53.2-64.1%)。长期 CDTi 使鞭虫和钩虫的患病率分别显著降低了 76.2%和 56.9%(p<0.001)。然而,CDTi 并没有影响蛔虫感染的患病率,相反,在当前研究中,蛔虫感染的患病率显著更高(p<0.001)。总体而言,CDTi 后的任何肠道寄生虫感染的患病率明显低于基线(p<0.001)。这表明,长期用于控制和消除盘尾丝虫病的 CDTi 除了降低肠道寄生虫感染(特别是鞭虫和钩虫)的患病率外,还有额外的健康益处,但对蛔虫感染没有影响。我们的研究结果表明,大规模伊维菌素给药的额外健康益处将有助于增加社区在 MDA 活动中的积极参与和持续参与,并加强政府和非政府组织(NGO)对正在进行的国家盘尾丝虫病消除计划的支持。